S&P 500   3,246.59 (+0.30%)
DOW   26,815.44 (+0.20%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
S&P 500   3,246.59 (+0.30%)
DOW   26,815.44 (+0.20%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
S&P 500   3,246.59 (+0.30%)
DOW   26,815.44 (+0.20%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
S&P 500   3,246.59 (+0.30%)
DOW   26,815.44 (+0.20%)
QQQ   265.39 (+0.47%)
AAPL   108.22 (+1.03%)
MSFT   203.19 (+1.30%)
FB   249.53 (+0.20%)
GOOGL   1,422.86 (+0.96%)
AMZN   3,019.79 (+0.66%)
NVDA   493.92 (+1.85%)
TSLA   387.79 (+1.95%)
BABA   269.73 (-1.18%)
CGC   14.27 (-2.26%)
GE   6.06 (-0.82%)
MU   49.47 (-0.76%)
AMD   75.82 (+1.46%)
T   28.04 (+0.61%)
F   6.66 (+0.30%)
ACB   5.20 (+0.58%)
GILD   62.25 (-1.33%)
NFLX   473.08 (+0.52%)
DIS   122.49 (-0.64%)
BAC   23.34 (+0.34%)
BA   146.05 (-3.39%)
Log in
LON:OXB

Oxford BioMedica Share Forecast, Price & News

GBX 841
+8.00 (+0.96 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
830
Now: GBX 841
850
50-Day Range
808
MA: GBX 837.60
865
52-Week Range
356.73
Now: GBX 841
899
Volume117,742 shs
Average Volume165,040 shs
Market Capitalization£690.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Immune Design, and Microsoft. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Read More
Oxford BioMedica logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.97 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1865-783000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£64.06 million
Cash FlowGBX 24.70 per share
Book ValueGBX 98.40 per share

Profitability

Miscellaneous

Employees432
Market Cap£690.71 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 841
+8.00 (+0.96 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OXB News and Ratings via Email

Sign-up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oxford BioMedica (LON:OXB) Frequently Asked Questions

How has Oxford BioMedica's stock price been impacted by COVID-19?

Oxford BioMedica's stock was trading at GBX 525 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OXB shares have increased by 60.2% and is now trading at GBX 841.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Oxford BioMedica?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Oxford BioMedica
.

What price target have analysts set for OXB?

3 analysts have issued twelve-month price targets for Oxford BioMedica's stock. Their forecasts range from GBX 730 to GBX 1,050. On average, they expect Oxford BioMedica's share price to reach GBX 926.67 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price.
View analysts' price targets for Oxford BioMedica
.

Who are some of Oxford BioMedica's key competitors?

What other stocks do shareholders of Oxford BioMedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford BioMedica investors own include Enquest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford BioMedica (OXBDF), Premier Oil (PMO), Afren (AFR), Barclays (BARC) and Genel Energy (GENL).

Who are Oxford BioMedica's key executives?

Oxford BioMedica's management team includes the following people:
  • Mr. John Dawson, CEO & Exec. Director (Age 59)
  • Mr. Stuart Paynter, CFO & Director
  • Mr. Timothy William Watts, Exec. Officer (Age 61)
  • Mr. Peter Nolan, Consultant (Age 66)
  • Mr. Nick Page, Chief Operations Officer

What is Oxford BioMedica's stock symbol?

Oxford BioMedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB."

How do I buy shares of Oxford BioMedica?

Shares of OXB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Oxford BioMedica's stock price today?

One share of OXB stock can currently be purchased for approximately GBX 841.

How big of a company is Oxford BioMedica?

Oxford BioMedica has a market capitalization of £690.71 million and generates £64.06 million in revenue each year. Oxford BioMedica employs 432 workers across the globe.

What is Oxford BioMedica's official website?

The official website for Oxford BioMedica is www.oxfordbiomedica.co.uk.

How can I contact Oxford BioMedica?

Oxford BioMedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000.

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.